Drug Profile
Research programme: ion channel modulators - Bristol-Myers Squibb/Icagen
Alternative Names: Atrial fibrillation therapy - IcagenLatest Information Update: 11 Feb 2008
Price :
$50
*
At a glance
- Originator Icagen
- Developer Bristol-Myers Squibb; Icagen
- Class Small molecules
- Mechanism of Action Ion channel modulators; Potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atrial fibrillation
Most Recent Events
- 08 Aug 2007 Bristol-Myers Squibb discontinues its development in this research programme
- 10 Aug 2006 Preclinical trials in Atrial fibrillation in USA (unspecified route)
- 21 Nov 2005 This compound is still in active development